Navigation Links
Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study

COPENHAGEN, June 21, 2007-Novo Nordisk today announced clinical results from the first of five phase 3 studies with liraglutide - the once-daily human GLP-1 analogue. The 26-week study is part of the LEAD(TM) (Liraglutide Effect and Action in Diabetes) programme and included 581 patients with type 2 diabetes inadequately controlled by two of the most widely used oral antidiabetic drugs: metformin and a sulfonylurea (glimepiride). All patients in the study continued the two oral drugs and were randomised to add one daily injection of liraglutide, placebo or insulin glargine.

The average HbA1c level at the beginning of the study was between 8.0% and 8.5% and at the end of the study, more than 50% of patients in the liraglutide group had reached the American Diabetes Association goal of HbA1c < 7%. Furthermore, more than 35% achieved the American Association of Clinical Endocrinologists HbA1c target of <= 6.5%. The HbA1c reduction achieved in the liraglutide group was more than 0.2 percentage points better than in the insulin glargine group, a difference which is statistically significant.

The average weight of the patients at the beginning of the study was approximately 85 kg. At the end of the study, the difference in body weight between the liraglutide and insulin glargine treatment groups was on average 3.5 kg, statistically significant in favour of liraglutide.

Liraglutide in combination with metformin and glimepiride was well tolerated. The most frequently reported adverse event in the liraglutide arm was nausea at an absolute level of between 10 and 15%. As expected, the combination of a GLP-1 analogue with a sulfonylurea leads to some of the patients experiencing hypoglycaemia. The overall hypoglycaemia event rate in the liraglutide and insulin glargine groups was not significantly different.

Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk, said: "We are very
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
2. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
3. Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients
4. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
5. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
6. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
7. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
8. 2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion
Post Your Comments:
(Date:2/27/2015)... Pa. , Feb. 27, 2015  In recognition ... ongoing commitment to the global bleeding disorders community, ... 2 million international units (IUs) of protein therapies to ... international not-for- profit organization which has worked to improve ... bleeding disorders. The donation supports the WFH,s Global Alliance ...
(Date:2/27/2015)... TEL-AVIV, Israel , February 27, 2015 ... Unternehmen baut sein bahnbrechendes Überwachungssystem für kongestive ... weiter aus -   ... Medical Technologies, die ein neuartiges Herzüberwachungssystem für ... gab heute bekannt, dass sie ein Finanzierungsvorhaben ...
(Date:2/27/2015)... YORK , Feb. 27, 2015 /PRNewswire/ ... are increasing in applications as their effectiveness ... firm Kalorama Information.  Kalorama Information says that ... is the most powerful tool in proteomic ... spec; MS) through its traditional techniques has ...
Breaking Medicine Technology:CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3
... A new study looking at in-person, electronic, telephonic, fax ... their medications concludes that pharmacists at a retail store ... patients to take medicine as prescribed. (Logo: ... of more than 40 years of studies published in ...
... 21, 2010 Takeda Pharmaceutical Company Limited ("Takeda") ... Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed ... against the companies in response to their Abbreviated ... HCl), ACTO plus met® (pioglitazone HCl and ...
Cached Medicine Technology:New Study Finds Pharmacists and Nurses are the Most Effective Health Care 'Voices' in Promoting Medication Adherence 2New Study Finds Pharmacists and Nurses are the Most Effective Health Care 'Voices' in Promoting Medication Adherence 3Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 2Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 3Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 4Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 5Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 6
(Date:2/28/2015)... Vegas, NV (PRWEB) February 28, 2015 My ... will be sending a team to Las Vegas, Nevada for ... Market Week is one of the leading consumer-goods tradeshows and ... vendors at this year’s event. My Shiney Hiney can be ... a fresh, modern design for the at-home personal hygiene brush ...
(Date:2/27/2015)... 27, 2015 Wireless Analytics, ... and one of the founders of the ... Bell Mobility within their CLEAN Platform™ (Communications Lifecycle ... Wireless Analytics’ newly developed Bell Mobility Data Loader ... Canadian wireless carrier’s business customers. , Wireless Analytics ...
(Date:2/27/2015)... Just a little over two years ago, ... Sjögren’s Syndrome after a new autoantibody associated with the ... of Buffalo and Immco Diagnostics, Inc. After the groundbreaking ... a new diagnostic test that would be ... Researchers aimed to develop a test that would more ...
(Date:2/27/2015)... On March 2-4, the Mesothelioma Applied ... Institute (NCI) will co-host the annual International Symposium ... Health (NIH), in Bethesda, Maryland. The event comprises ... professionals and scientists who specialize in mesothelioma, while ... including patients, their families, and caregivers. , The ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Altec Products, ... as their Sage ERP Document Management Partner of the ... ERP, Sage CRM and other complimentary solutions for their ... worked side-by-side for many years to provide clients with ... applications. , “We are thrilled to recognize ADSS ...
Breaking Medicine News(10 mins):Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Breakthrough Blood Test for Early Detection of Sjögren’s Syndrome Now Available 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3Health News:Altec Announces 2014 Sage ERP Document Management Partner of the Year Award Recipient 2
... , , SOUTHBOROUGH, Mass., Aug. 26 ... toll worldwide this season, and experts say the new flu strain is expected ... end up being affected by the H1N1 flu, the C ... H1N1 alert to pandemic status, its highest level. What does this mean ...
... LOS ANGELES, Aug. 26 Sports-related eye injuries are a leading cause ... hard blow to the eye, they should be examined, even if there ... educate the public about vision protection, The Vision Center at Childrens Hospital ... this September. , , According to Dr. Mark ...
... , SMITHFIELD, R.I., Aug. 26 A series of free ... of employer-based Hearing Conservation Programs have been announced for eight cities along the ... L eight (R)/ Sperian Hear i ng Protection ... HearForever(TM): Be s t Practices ...
... , SARASOTA, Fla., Aug. 26 ... that it proposes to offer, subject to market and other considerations, senior ... rate, principal amount and maturity, will depend on market conditions at the ... sale of the notes will be used to repay borrowings under Roper,s ...
... Cancer Metastasis Dr. Amanda Harvey and colleagues at ... role in breast cancer progression and dissemination. Their report ... American Journal of Pathology . Breast ... cancer patients. Non-metastatic breast cancer cells rely on interactions ...
... , , , ... Medical, Inc. (Nasdaq: SLTM ) today announced the launch ... large body areas during a single treatment. Prior to the non-ablative ... to the face. The Fraxel re:store Dual takes the industry leading ...
Cached Medicine News:Health News:Monitoring for Fever Can Help With Early Detection of H1N1 - 'Swine Flu' 2Health News:September is Vision Safety Month at the Vision Center CHLA: Sports Eye Injuries a Leading Cause of Blindness in Children 2Health News:September is Vision Safety Month at the Vision Center CHLA: Sports Eye Injuries a Leading Cause of Blindness in Children 3Health News:Free Seminars Will Detail Best Practices in Employer Hearing Conservation, Impending NRR Change 2Health News:Free Seminars Will Detail Best Practices in Employer Hearing Conservation, Impending NRR Change 3Health News:Free Seminars Will Detail Best Practices in Employer Hearing Conservation, Impending NRR Change 4Health News:Roper Industries Announces Proposed Public Offering of Senior Unsecured Notes due 2019 2Health News:Roper Industries Announces Proposed Public Offering of Senior Unsecured Notes due 2019 3Health News:Tips from the American Journal of Pathology 2Health News:Tips from the American Journal of Pathology 3Health News:Tips from the American Journal of Pathology 4Health News:Tips from the American Journal of Pathology 5Health News:Solta Medical Launches New Fraxel re:store(R) Dual Laser System 2Health News:Solta Medical Launches New Fraxel re:store(R) Dual Laser System 3
... is an automated blood gas analysis system ... reduce the steps in the analytical process, ... errors. The 1st automatic system consists of ... and FLEXQ automatic sample handling system. With ...
... RAPID Reader - Portable RAPIDViewing Software., ... Given Diagnostic System, which can be installed on ... to open Patient RAPID Report (PRR) videos created ... to save them, at home or on the ...
... is a unique tool that ... commands to activate shortcut keys ... the need to perform manual ... can devote your full attention ...
... Application for POLYGRAM NET™ (PNET) works ... to record and analyze pressure and ... The PNET software and Polygraf ID ... as well as self-adhesive cutaneous and ...
Medicine Products: